Log in to save to my catalogue

AtezoTRIBE: a randomised phase II study of FOLFOXIRI plus bevacizumab alone or in combination with a...

AtezoTRIBE: a randomised phase II study of FOLFOXIRI plus bevacizumab alone or in combination with a...

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_9d9f7151e67a49a2a5095a5c6c078498

AtezoTRIBE: a randomised phase II study of FOLFOXIRI plus bevacizumab alone or in combination with atezolizumab as initial therapy for patients with unresectable metastatic colorectal cancer

About this item

Full title

AtezoTRIBE: a randomised phase II study of FOLFOXIRI plus bevacizumab alone or in combination with atezolizumab as initial therapy for patients with unresectable metastatic colorectal cancer

Publisher

England: BioMed Central Ltd

Journal title

BMC cancer, 2020-07, Vol.20 (1), p.683-9, Article 683

Language

English

Formats

Publication information

Publisher

England: BioMed Central Ltd

More information

Scope and Contents

Contents

Immune checkpoint inhibitors (ICIs) reported remarkable achievements in several solid tumours. However, in metastatic colorectal cancer (mCRC) promising results are limited to patients with deficient mismatch repair/microsatellite instability-high (dMMR/MSI-high) tumours due to their immune-enriched microenvironment. Combining cytotoxic agents and...

Alternative Titles

Full title

AtezoTRIBE: a randomised phase II study of FOLFOXIRI plus bevacizumab alone or in combination with atezolizumab as initial therapy for patients with unresectable metastatic colorectal cancer

Identifiers

Primary Identifiers

Record Identifier

TN_cdi_doaj_primary_oai_doaj_org_article_9d9f7151e67a49a2a5095a5c6c078498

Permalink

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_9d9f7151e67a49a2a5095a5c6c078498

Other Identifiers

ISSN

1471-2407

E-ISSN

1471-2407

DOI

10.1186/s12885-020-07169-6

How to access this item